These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8911867)

  • 1. HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.
    Leal M; Torres Y; Medrano FJ; Rey C; Caruz A; Sánchez-Quijano A; Lissen E
    Eur J Clin Invest; 1996 Oct; 26(10):923-8. PubMed ID: 8911867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
    Hughes MD; Johnson VA; Hirsch MS; Bremer JW; Elbeik T; Erice A; Kuritzkes DR; Scott WA; Spector SA; Basgoz N; Fischl MA; D'Aquila RT
    Ann Intern Med; 1997 Jun; 126(12):929-38. PubMed ID: 9182469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine.
    Rubio A; Leal M; Rey C; Pineda JA; Sanchez-Quijano A; Lissen E
    AIDS; 1998 Mar; 12(4):395-8. PubMed ID: 9520169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS; DeMasi R; Hill AM
    AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
    van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
    J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
    Rubio A; Gómez-Cano M; Puig T; Leal M; Pérez-Olmeda M; Ruiz L; Clotet B; Rey C; Zamora L; Xaus N; Soriano V
    Antivir Ther; 1999; 4(1):45-9. PubMed ID: 10682128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD
    Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine.
    Torres Y; Leal M; Rey C; Medrano FJ; Sánchez-Quijano A; Lissen E
    Eur J Clin Microbiol Infect Dis; 1996 Apr; 15(4):324-7. PubMed ID: 8781884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of HIV-1 RNA during antiretroviral therapy: association with viral phenotype and development of resistance.
    Katzenstein TL; Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    Antivir Ther; 1996 Dec; 1(4):246-54. PubMed ID: 11324827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
    van 't Wout AB; Ran LJ; Nijhuis M; Tijnagel JM; de Groot T; van Leeuwen R; Boucher CA; Schuitemaker H; Schuurman R
    AIDS; 1998 Jul; 12(10):1169-76. PubMed ID: 9677166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
    D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD
    Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.
    Naugler WE; Yong FH; Carey VJ; Dragavon JA; Coombs RW; Frenkel LM
    J Infect Dis; 2002 Feb; 185(4):448-55. PubMed ID: 11865396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
    Holodniy M; Katzenstein D; Mole L; Winters M; Merigan T
    J Infect Dis; 1996 Oct; 174(4):854-7. PubMed ID: 8843229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.